Related Experiment Video

Updated: Jun 12, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K

Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC

Georgia Gomatou1, Andriani Charpidou2, Peifeng Li3

  • 1Oncology Unit, Third Department of Medicine, "Sotiria" General Hospital for Chest Diseases, National and Kapodistrian University of Athens, Athens, Greece. georgiagom@med.uoa.gr.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|September 22, 2024
PubMed

Insights

Immune checkpoint inhibitors (ICIs) offer survival benefits for non-small cell lung cancer (NSCLC) but resistance is common. Understanding primary resistance mechanisms is crucial for developing new treatments for NSCLC patients.

Area of Science:

  • Oncology
  • Immunotherapy
  • Thoracic Malignancies

Background:

  • Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment, improving survival and response durability.
  • However, a significant proportion of patients develop primary or acquired resistance to ICIs.
  • Defining primary resistance in NSCLC, especially with evolving early-stage treatment regimens, remains challenging.

Purpose of the Study:

  • To review the challenges in defining and understanding primary resistance to ICIs in NSCLC.
  • To explore the complex mechanisms underlying primary ICI resistance in NSCLC.
  • To discuss current management strategies and future research directions for NSCLC patients with primary ICI resistance.

Main Methods:

  • Literature review of current research on ICI resistance in NSCLC.
  • Analysis of mechanisms involving tumor cells, tumor microenvironment, and host factors.
  • Discussion of clinical challenges and therapeutic strategies.

Main Results:

  • Primary resistance to ICIs in NSCLC is multifactorial, involving complex interactions between tumor and host.
  • An immunosuppressive tumor phenotype is a key feature of primary resistance.
  • Optimal management of primary ICI resistance in NSCLC is an unmet clinical need.

Conclusions:

  • Primary resistance to ICIs is a significant hurdle in NSCLC treatment.
  • Further research into resistance mechanisms is essential for therapeutic advancements.
  • Exploring alternative immunotherapies and novel drug conjugates holds promise for overcoming ICI resistance in NSCLC.
Keywords:
Immune checkpoint inhibitorsImmunotherapyNSCLCPrimary resistanceResistance

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

305
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
858
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
686
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K